Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Division of Allergy/Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.
Eosinophils are important effector cells and therapeutic targets in allergic diseases. Emerging data indicate that eosinophils infiltrate a variety of solid tumor types and have pleiotropic activities by at least two non-mutually exclusive mechanisms: direct interactions with tumor cells, and intricate cross-talk with lymphocytes. In light of the immune checkpoint inhibition revolution in cancer therapy, we review eosinophil-lymphocyte interactions in the tumor microenvironment. We also analyze potential interactions between eosinophils and lymphocyte subsets, including T cells, natural killer cells and innate lymphoid cells. We provide perspectives on the consequences of these interactions and how eosinophils are accessory cells that can affect the response to various forms of T cell-mediated immunotherapies and might be therapeutically targeted to improve cancer immunotherapy.
嗜酸性粒细胞是过敏疾病中重要的效应细胞和治疗靶点。新出现的数据表明,嗜酸性粒细胞浸润多种实体肿瘤类型,并通过至少两种非相互排斥的机制发挥多效性作用:与肿瘤细胞的直接相互作用,以及与淋巴细胞的复杂串扰。鉴于癌症治疗中的免疫检查点抑制革命,我们回顾了肿瘤微环境中的嗜酸性粒细胞-淋巴细胞相互作用。我们还分析了嗜酸性粒细胞与淋巴细胞亚群(包括 T 细胞、自然杀伤细胞和先天淋巴细胞)之间潜在的相互作用。我们提供了对这些相互作用后果的看法,以及嗜酸性粒细胞如何作为辅助细胞影响对各种形式的 T 细胞介导的免疫疗法的反应,并可能作为治疗靶点来改善癌症免疫疗法。